These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1339 related articles for article (PubMed ID: 24331822)

  • 21. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA; Campos NG; Sy S; Regan C; Kim JJ
    Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
    Goldie SJ; O'Shea M; Diaz M; Kim SY
    Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.
    Diaz M; Kim JJ; Albero G; de Sanjosé S; Clifford G; Bosch FX; Goldie SJ
    Br J Cancer; 2008 Jul; 99(2):230-8. PubMed ID: 18612311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
    Kim SY; Sweet S; Chang J; Goldie SJ
    BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of human papillomavirus-related cervical disease in the extended middle East and north Africa-a comprehensive literature review.
    Seoud M
    J Low Genit Tract Dis; 2012 Apr; 16(2):106-20. PubMed ID: 22371041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
    Kiatpongsan S; Kim JJ
    PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barriers to human papillomavirus vaccine acceptability in Israel.
    Fisher WA; Laniado H; Shoval H; Hakim M; Bornstein J
    Vaccine; 2013 Nov; 31 Suppl 8():I53-7. PubMed ID: 24229720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
    Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
    Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries.
    Campos NG; Sharma M; Clark A; Lee K; Geng F; Regan C; Kim J; Resch S
    Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():47-56. PubMed ID: 28691334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
    Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.